John Ireton, DO
Hospitalist · Logan, OHNPI 1821087610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $433 and has fallen 84.1% since, to $69 in 2025. Among hospitalist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$369
- AbbVie$217
- AstraZeneca$165
- Pfizer$126
- Amgen$105
- Bayer$96
- plus $653 from 20 others
What the payments were for
- Food & beverage$1,730100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $369 |
| AbbVie | 13 | $217 |
| AstraZeneca | 11 | $165 |
| Pfizer | 8 | $126 |
| Amgen | 6 | $105 |
| Bayer | 6 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $87 |
| Merck | 4 | $73 |
| Lilly USA, LLC | 5 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Novartis | 2 | $46 |
| GSK | 3 | $45 |
| Corcept Therapeutics | 2 | $36 |
| Medtronic(2 entities) | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Boehringer Ingelheim | 2 | $25 |
| Abbott | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$1,730 in reported general payments places this provider in the 95th percentile of 813 hospitalist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 27 | $23,740 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $11,411 |
| EliquisApixaban | 12 | $10,914 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $5,681 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $5,478 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,152 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $2,356 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,007 |
| Colestipol Hcl | 19 | $1,785 |
| Irbesartan | 76 | $1,507 |
| Montelukast Sodium | 127 | $1,224 |
| Potassium Chloride | 41 | $1,193 |
| Levetiracetam | 14 | $922 |
| Gabapentin | 70 | $891 |
| Pantoprazole Sodium | 60 | $880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $30 | $23,74027 claims |
| GSKTrelegy Ellipta | $45 | $11,41121 claims |
| PfizerEliquis | $126 | $10,91412 claims |
| MerckJanumet Xr | $73 | $5,68111 claims |
| AbbVieSynthroid | $217 | $61018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 813 hospitalist providers in Ohio.
Other hospitalist in Logan
- Chandramohan MeenakshisundaramCleveland$54K
- Kirshan LalDayton$28K
- Geeta SrivastavaCincinnati$10K
- Danielle ClemmerColumbus$9K
- Robert RubinCincinnati$9K
- Roop KawCleveland$8K
- Rohit UppalColumbus$6K
- Patrick GradyCleveland$6K
- Andre FabienCleveland$6K
- Beth ListonColumbus$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.